RxDoctor Payments DataLook up a doctor →

Drew Uhrig, MD

Neurology · Birmingham, ALNPI 1578829834

Payments from drug & device makers

$33,605in general payments, 2019–2025

Across 1,934 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Novartis$2K
  • UCB, Inc.$2K
  • Biogen$2K
  • AstraZeneca$1K
  • Amgen$1K
  • plus $20K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)366$5,144
Novartis134$2,337
UCB, Inc.107$2,035
Biogen108$1,501
AstraZeneca(2 entities)68$1,409
Amgen(2 entities)72$1,242
Lundbeck LLC55$1,160
Pfizer64$1,051
Neurocrine Biosciences, Inc.52$1,050
Lilly USA, LLC68$1,042
Acorda Therapeutics, Inc59$1,022
MDD US Operations, LLC15$874
Genentech USA, Inc.49$868
Teva Pharmaceuticals USA, Inc.55$829
Acadia Pharmaceuticals Inc50$748
EMD Serono, Inc.41$745
CSL Behring21$738
Upsher-smith Laboratories LLC41$708
SK Life Science, Inc.34$660
Eisai Inc.33$644
Impel Pharmaceuticals Inc.27$475
Supernus Pharmaceuticals, Inc.30$446
Johnson & Johnson(2 entities)33$443
Argenx US, Inc.22$438
Amneal Pharmaceuticals LLC30$429
Catalyst Pharmaceuticals, Inc.21$381
Biohaven Pharmaceuticals, Inc.27$374
Tanabe Pharma America, Inc.18$336
Sanofi15$332
Takeda Pharmaceuticals U.S.A., Inc.14$294
Avanir Pharmaceuticals, Inc.15$265
Biohaven Pharmaceutical Holding Company Ltd.18$249
Bristol Myers Squibb14$244
Grifols USA, LLC10$191
Neurelis, Inc.11$183
Adamas Pharmaceuticals, Inc.8$175
Sumitomo Pharma America, Inc.7$163
Ipsen Biopharmaceuticals, Inc7$162
Assertio Therapeutics, Inc.10$146
Merz Pharmaceuticals, LLC6$143
Axsome Therapeutics, Inc.5$131
Kyowa Kirin, Inc.7$131
Akcea Therapeutics, Inc.7$126
Sunovion Pharmaceuticals Inc.9$118
TG Therapeutics, Inc.5$117
Greenwich Biosciences, Inc.6$113
Jazz Pharmaceuticals Inc.4$90
Otsuka America Pharmaceutical, Inc.4$86
Almatica Pharma LLC5$86
Avion Pharmaceuticals5$77
Alnylam Pharmaceuticals Inc.3$75
Cycle Pharmaceuticals Inc2$73
ANI Pharmaceuticals, Inc.3$64
Mallinckrodt Hospital Products Inc.3$62
Aquestive Therapeutics, Inc.3$57
Scilex Pharmaceuticals Inc.3$57
Boston Scientific3$56
Vanda Pharmaceuticals Inc.2$52
Arbor Pharmaceuticals, Inc.3$45
Merz North America, Inc.1$39

How this compares

$33,605 in reported general payments places this provider in the 75th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama →

Medicare billing

Part B allowed, 2024
$227,850
Medicare patients
431
Services billed
16,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Birmingham

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →